| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000022863 |
| Receipt No. | R000026349 |
| Official scientific title of the study | A Study on the Effect of whey protein hydrolysate on Postprandial Blood Glucose |
| Date of disclosure of the study information | 2016/06/24 |
| Last modified on | 2016/08/19 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | A Study on the Effect of whey protein hydrolysate on Postprandial Blood Glucose | |
| Title of the study (Brief title) | The Effect of whey protein hydrolysate on Postprandial Blood Glucose | |
| Region |
|
|
| Condition | |||
| Condition | Not applicable | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To explore inhibitory effect of whey protein hydrolysate on postprandial blood glucose level. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Postprandial blood glucose level |
| Key secondary outcomes | Blood insulin level
Blood C-peptide level Blood total amino acid level Blood BCAA level |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -investigator(s) and assessor(s) are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | NO |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Whey protein hydrolysate, single ingestion. Wash out 1 week. Placebo, single ingestion | |
| Interventions/Control_2 | Placebo, single ingestion. Wash out 1 week. Whey protein hydrolysate, single ingestion | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1) Subjects who can make self-judgment and are voluntarily giving written informed consent.
2) Males whose age 40 to 59 years old and meet the following conditions (1) and/or (2) at the day of screening test. (1) Fasting blood glucose level is 100mg/dL to less than 126 mg/dL. (2) HbA1c value is 5.8 to less than 6.5% (NGSP). |
|||
| Key exclusion criteria | 1) Seriously or progressive ill patients
2) Subjects who use pharmaceuticals regularly. 3) Subjects with food allergies 4) Subjects who excessive alcohol intake. (intake over 60g alcohol per day) 5) Subjects who have a smoking habit. 6) Subjects who donated 400 mL of blood within 12 weeks. Subjects who donated 200 mL of blood within 4 weeks. Subject who donated platelet blood within 2weeks. 7) Fasting blood glucose level over 126mg/dL, or HbA1c over 6.5% at the day of screening test. 8) Others who have been determined ineligible by principal investigator or sub-investigator. |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Kentaro Kawanaka |
| Organization | Fukuoka University |
| Division name | Faculty of Sports and Health Science |
| Address | 8-19-1, Nanakuma, Jonan-ku, Fukuoka City, Fukuoka, 814-0180, Japan |
| TEL | +81-92-871-6631 |
| kawanaka@fukuoka-u.ac.jp | |
| Public contact | |
| Name of contact person | Shihoko Nakashima |
| Organization | Fukuoka University |
| Division name | Faculty of Sports and Health Science |
| Address | 8-19-1, Nanakuma, Jonan-ku, Fukuoka City, Fukuoka, 814-0180, Japan |
| TEL | +81-92-871-6631 |
| Homepage URL | |
| shihoko@fukuoka-u.ac.jp | |
| Sponsor | |
| Institute | Fukuoka University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Meiji Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026349 |